5 Cheap Biotech Stocks To Buy
Since the company's July 2021 IPO, CRISPR Therapeutics AG (NASDAQ:CRSP) shares have fallen by 44%.
Innoviva Inc. (INVA)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | AlphaCrest Capital Management Mika Toikka | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.46 | 10,000 | Director | 124,560 | 2021-05-24 | Filing | |
| $12.97 | 10,000 | Director | 114,560 | 2021-05-21 | Filing | |
| $14.90 | 10,000 | Director | 38,762 | 2019-02-21 | Filing | |
| $14.80 | 7,000 | Officer | 7,000 | 2019-02-15 | Filing | |
| $3,485,841.04 | 245,828 | Large Shareholder | 32,005,260 | 2015-08-07 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $15.89 | 1,129 | Officer | 35,364 | 2021-08-20 | Filing | |
| $15.89 | 1,129 | Officer | 35,364 | 2021-08-20 | Filing | |
| $16.02 | 2,802 | Officer | 36,493 | 2021-08-19 | Filing | |
| $12.25 | 32,005,260 | Large Shareholder | 0 | 2021-05-20 | Filing | |
| $14.78 | 2,954 | Officer | 21,913 | 2020-02-24 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 18,562,000 | $19,009,344 | 0.08% | |
| 2. | 271,052 | $3,591,439 | 0% | |
| 3. | 150,912 | $1,999,584 | 0.05% | |
| 4. | 77,590 | $1,028,068 | 0.75% | |
| 5. | 53,735 | $711,989 | 0.42% |
News See All
12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds
In this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds.
Hedge Fund and Insider Trading News: Carl Icahn, Warren Buffett, Bill Ackman, Ray Dalio, Elliott Management, Assurant Inc. (AIZ), Innoviva Inc (INVA), and More
Billionaire investor Carl Icahn has been a hard-charging shareholder activist for decades.
Is INVA A Good Stock To Buy According To Hedge Funds?
With the third-quarter round of 13F filings behind us it is time to take a look at the stocks in which some of the best money managers in the world preferred to invest or sell heading into the fourth ...
Innoviva, Inc. (INVA): Hedge Funds Are Cautiously Waiting On The Sidelines
We know that hedge funds generate strong, risk-adjusted returns over the long run, which is why imitating the picks that they are collectively bullish on can be a profitable strategy for retail investors...
Did Hedge Funds Make The Right Call On Innoviva, Inc. (INVA)?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (see why hell is coming).
Here is What Hedge Funds Think About Innoviva, Inc. (INVA)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Were Hedge Funds Right About Innoviva, Inc. (INVA)?
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds.
How Did Innoviva, Inc. (INVA) Compare Against Hedge Fund Darlings in 2019?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not...
Hedge Funds Have Never Been More Bullish On Innoviva, Inc. (INVA)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Billionaire Hedge Funds
